Resultados de la búsqueda 1041-1050 of 6746 for Selective mutism

  1. Ensayos clínicos - Neurología

    The purpose of this registry is to collect clinical, diagnostic, and therapeutic data specific for primary spinal column tumor patients, and evaluate it to ...

  2. Oncología (médica) - Ensayos clínicos

    The purpose of this study is to find the maximum tolerated dose of iberdomide for patients newly diagnosed with multiple myeloma, and to determine response ...

  3. Ensayos clínicos - Neurología

    The purpose of this study is to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a ...

  4. Medicina cardiovascular - Ensayos clínicos

    The postnatal diagnosis of Long QT Syndrome (LQTS) is suggested by a prolonged QT interval on 12 lead electrocardiogram (ECG),a positive family history ...

  5. Oncología (médica) - Ensayos clínicos

    The purpose of this study is to culture human mammary cells to identify cellular characteristics associated with lobular involution status. Cutaneous Lymphoma ...

  6. Ensayos clínicos - Neurología

    The purpose of this study is to evaluate plasma biomarkers of vascular function and inflammation in patients with newly-diagnosed Obstructive Sleep Apnea (OSA) ...

  7. Mayo Clinic

    Share · Tweet. Ver también. Absceso dental · Agammaglobulinemia ligada al cromosoma X · Anafilaxia · Anorgasmia en mujeres · Ataxia · Bronquitis ...

  8. Oncología (médica) - Ensayos clínicos

    Rochester, Minn. The purpose of this study is to evaluate how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

  10. Oncología (médica) - Ensayos clínicos

    Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...